|
시장보고서
상품코드
2049667
에피제네틱스 시장 보고서 : 제품별, 기술별, 용도별, 지역별(2026-2034년)Epigenetics Market Report by Product, Technology, Application, and Region 2026-2034 |
||||||
2025년, 세계의 에피제네틱스 시장 규모는 30억 달러에 달했습니다. 향후에 대해 IMARC Group은 2026-2034년에 CAGR 11.54%로 성장하며, 2034년까지 시장 규모가 83억 달러에 달할 것으로 예측하고 있습니다.
후성유전학은 활성 및 비활성 유전자의 발현에서 유전 가능한 변화를 연구하는 학문입니다. 변화의 원인은 환경적 요인과 같은 외적 요인뿐만 아니라 노화나 질병과 같은 내적 요인도 있습니다. 이는 일반적으로 기저질환을 진단하거나 다음 세대로의 전이를 예방하기 위해 활용되고 있습니다. 여기에는 다양한 효소, 시퀀서, 분광계, 초음파 처리 장치 등의 장비, 시약, 키트의 사용이 포함됩니다. 이들은 데옥시리보핵산(DNA) 및 히스톤의 메틸화, 비코드 리보핵산(RNA), 아세틸화, 인산화 분석에 널리 이용되고 있습니다. 그 결과, 후성유전학은 종양질환, 자가면역질환, 대사질환, 심혈관질환, 통증질환의 진단, 모니터링, 치료에 널리 활용되고 있습니다.
에피제네틱스 시장 동향:
전 세계 암 및 후천성면역결핍증후군(AIDS)의 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한 비종양성 질환에 대한 후성유전학 솔루션의 보급이 시장 성장에 탄력을 받고 있습니다. 신종 코로나바이러스 감염증(COVID-19)의 갑작스러운 확산도 시장 관계자들에게 성장의 기회를 가져다주고 있습니다. 예를 들어 여러 연구기관에서 바이러스가 인간 게놈에 미치는 영향을 조사하기 위해 고급 후성유전학 검사를 실시하여 조기 발견, 위험 평가 및 개인별 맞춤 치료를 위한 툴을 개발하고 있습니다. 또한 아세틸라제, 메틸전이효소, 역전사효소, 리가제 등 DNA 및 RNA 변형효소의 개발 및 고감도, 고선택성 검사법 및 기기의 등장도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이러한 혁신을 통해 게놈의 유전자좌별 DNA 메틸화를 평가할 수 있게 되었습니다. 생명공학 분야의 광범위한 연구개발(R&D) 활동, 특히 개발도상국의 의료 인프라의 대폭적인 개선 등 다른 요인들도 시장 성장을 촉진할 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문
- 세계 후성유전학 시장 규모는 어느 정도인가?
- 2026-2034년 세계의 후성유전학 시장의 예상 성장률은 어느 정도인가?
- 세계의 후성유전학 시장을 촉진하는 주요 요인은 무엇인가?
- COVID-19는 글로벌 후성유전학 시장에 어떤 영향을 미쳤는가?
- 제품별로 보면 글로벌 에피제네틱스 시장은 어떻게 구성되어 있는가?
- 세계의 후성유전학 시장은 기술별로 어떻게 분류되고 있는가?
- 세계 후성유전학 시장의 용도별 시장 현황은?
- 세계 후성유전학 시장의 주요 지역은 어디인가?
- 세계의 에피제네틱스 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 에피제네틱스 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 기술별
제8장 시장 내역 : 용도별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSAThe global epigenetics market size reached USD 3.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.3 Billion by 2034, exhibiting a growth rate (CAGR) of 11.54% during 2026-2034.
Epigenetics refers to the study of heritable changes in the expression of active and inactive genes. The sources of changes can be both external from environmental factors or internal factors, such as age and disease. It is commonly used for the diagnosis of underlying conditions and preventing them from getting transferred to the future generations. It involves the use of various enzymes, instruments, such as sequencers, spectrometers and sonicators, reagents and kits. They are commonly utilized for deoxyribonucleic acid (DNA) and histone methylation, non-coding ribonucleic acid (RNA), acetylation and phosphorylation. As a result, epigenetics is widely used for the diagnosis, monitoring and treatment of oncological, autoimmune, metabolic, cardiovascular and pain disorders.
EPIGENETICS MARKET TRENDS:
The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth. Moreover, the widespread adoption of epigenetic solutions for non-oncological ailments is providing a thrust to the market growth. The sudden outbreak of the coronavirus disease (COVID-19) is also providing growth opportunities to market players. For instance, various research institutes are running advanced epigenetic tests to study the impact of the virus on the human genome and are developing tools for early recognition, risk evaluations and developing personalized treatments. Additionally, the development of DNA and RNA modifying enzymes, such as acetylases, methyltransferases, reverse transcriptase and ligases, and the launch of highly sensitive and selective tests and instruments, are acting as other growth-inducing factors. These innovations facilitate the assessment of locus-specific DNA methylation on a genome. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Reagents
- Kits
- Chip Sequencing Kit
- Whole Genomic Amplification Kit
- Bisulfite Conversion Kit
- RNA Sequencing Kit
- Others
- Instruments
- Enzymes
- Services
Breakup by Technology:
- DNA Methylation
- Histone Methylation
- Histone Acetylation
- Large Non-Coding RNA
- MicroRNA Modification
- Chromatin Structures
Breakup by Application:
- Oncology
- Solid Tumors
- Liquid Tumors
- Non-Oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.
Key Questions Answered in This Report
- 1.How big is the global epigenetics market?
- 2.What is the expected growth rate of the global epigenetics market during 2026-2034?
- 3.What are the key factors driving the global epigenetics market?
- 4.What has been the impact of COVID-19 on the global epigenetics market?
- 5.What is the breakup of the global epigenetics market based on the product?
- 6.What is the breakup of the global epigenetics market based on the technology?
- 7.What is the breakup of the global epigenetics market based on the application?
- 8.What are the key regions in the global epigenetics market?
- 9.Who are the key players/companies in the global epigenetics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Epigenetics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Reagents
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Kits
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Chip Sequencing Kit
- 6.2.2.2 Whole Genomic Amplification Kit
- 6.2.2.3 Bisulfite Conversion Kit
- 6.2.2.4 RNA Sequencing Kit
- 6.2.2.5 Others
- 6.2.3 Market Forecast
- 6.3 Instruments
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Enzymes
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Services
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Technology
- 7.1 DNA Methylation
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Histone Methylation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Histone Acetylation
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Large Non-Coding RNA
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 MicroRNA Modification
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Chromatin Structures
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Application
- 8.1 Oncology
- 8.1.1 Market Trends
- 8.1.2 Key Segments
- 8.1.2.1 Solid Tumors
- 8.1.2.2 Liquid Tumors
- 8.1.3 Market Forecast
- 8.2 Non-Oncology
- 8.2.1 Market Trends
- 8.2.2 Key Segments
- 8.2.2.1 Inflammatory Diseases
- 8.2.2.2 Metabolic Diseases
- 8.2.2.3 Infectious Diseases
- 8.2.2.4 Cardiovascular Diseases
- 8.2.2.5 Others
- 8.2.3 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abcam plc
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Active Motif Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Agilent Technologies Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Diagenode Diagnostics (Hologic Inc)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Illumina Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Merck KGaA
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 PerkinElmer Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Roche Holding AG
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.9 Thermo Fisher Scientific Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Zymo Research Corporation
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.1 Abcam plc
